|
Exercise Plus Epoetin Alfa in Treating Cancer Patients Who Have Anemia-Related Fatigue Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified medical advice, calls or professional assistance using a genuine dr.. We aren't physicians. Always confer with your dr. on Exercise Plus Epoetin Alfa in Treating Cancer Patients Who Have Anemia-Related Fatigue conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Exercise Plus Epoetin Alfa in Treating Cancer Patients Who Have Anemia-Related Fatigue Clinical research trials and Exercise Plus Epoetin Alfa in Treating Cancer Patients Who Have Anemia-Related Fatigue medical trials happen in hundreds of localities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically measure the effectualness of new does drugs. The intent of the studies / undertakings is to answer particular human health questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to find cures for all kinds of circumstances, like Exercise Plus Epoetin Alfa in Treating Cancer Patients Who Have Anemia-Related Fatigue. Exercise Plus Epoetin Alfa in Treating Cancer Patients Who Have Anemia-Related Fatigue Clinical Trials and other clinical trials permit volunteers to acquire healthcare treatment options before they are available to the general public. Some times the subjects acquire professional assistance for free, and sometimes they are paid for their time. Sometimes there is a cost for a Exercise Plus Epoetin Alfa in Treating Cancer Patients Who Have Anemia-Related Fatigue clinical trial. Participants frequently obtain the most expert healthcare available for their Exercise Plus Epoetin Alfa in Treating Cancer Patients Who Have Anemia-Related Fatigue condition. Dangers are a reality, nevertheless, and can include more or frequent doctor calls, health risks (potentially life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "E" Clinical Trials Conditions > Exercise Plus Epoetin Alfa in Treating Cancer Patients Who Have Anemia-Related Fatigue  Exercise Plus Epoetin Alfa in Treating Cancer Patients Who Have Anemia-Related Fatigue
Exercise Plus Epoetin Alfa in Treating Cancer Patients Who Have Anemia-Related Fatigue
For Condition: unspecified adult solid tumor, protocol specific,Anemia,Fatigue
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , Robert H. Lurie Cancer Center
Synopsis: RATIONALE: Exercise may decrease anemia -related fatigue, improve strength, and build up lost muscle tissue. Epoetin alfa may help improve cancer-related anemia, energy levels, and quality of life. Exercise plus epoetin alfa may be effective treatment for anemia-related fatigue. PURPOSE: Phase II trial to study the effectiveness of exercise plus epoetin alfa in treating cancer patients who have anemia-related fatigue.
Details: OBJECTIVES: I. Determine the effect of progressive resistance training and epoetin alfa on lean body mass, fatigue, exercise tolerance, functional capacity, and total body weight in cancer patients with anemia related fatigue. PROTOCOL OUTLINE: Patients undergo progressive resistance training (PRT) consisting of 3 sets of 8 repetitions of concentric (lifting) and eccentric (lowering) exercises over 4-6 seconds each using bench press, arm pull, knee extension, knee flexion, and double leg press followed by 1-2 minutes of rest between sets. Patients undergo warm up and cool down periods over 10 minutes prior to and following PRT. Patients perform PRT 3 times a week for 12 weeks. Patients also receive epoetin alfa subcutaneously once weekly over 4-12 weeks in the absence of unacceptable toxicity. PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study over 15 months.
Eligibility:
Study Type: Interventional, Educational/Counseling/Training
Minimum Age/Maximum Age: 18 Years/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Diagnosis of nonmyeloid malignancy with cancer related fatigue - Anemia (hemoglobin less than 10 g/dL) - No clinical or radiographic evidence of lytic bone metastases --Prior/Concurrent Therapy-- - Biologic therapy: At least 8 weeks since prior epoetin alfa - Chemotherapy: Concurrent chemotherapy allowed - Endocrine therapy: Not specified - Radiotherapy: Concurrent radiotherapy allowed - Surgery: Not specified - Other: Concurrent anticancer therapy allowed; At least 1 month since prior strength training of greater than 3 hours a week --Patient Characteristics-- - Age: Over 18 - Performance status: ECOG 0-2 - Life expectancy: Greater than 4 months - Hematopoietic: See Disease Characteristics - Hepatic: Not specified - Renal: Not specified - Other: No dementia or evidence of mental incompetence; No physical handicap precluding aerobic or resistance exercise; No clinical abnormality that would render exercise a risk; HIV negative; No contraindications to epoetin alfa; Not pregnant or nursing; Negative pregnancy test
Total Enrollment:
Location and Contact Information:
Overall Study Official:
JamieVon Roenn, Study Chair, Robert H. Lurie Cancer Center
Robert H. Lurie Comprehensive Cancer Center, Northwestern University
Chicago, Illinois, 60611-3013
United States
Additional Information:
Study ID Numbers: CDR0000067594; NU-98CC7,NCI-G00-1706
Study Start Date: January 2000
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00004914
Other Anemia Studies:
1. Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
2. RO0503821 Treatment for Correction of Anemia in Chronic Kidney Disease Patients
3. RO0503821 for the Maintenance Treatment of Anemia in Patients with Chronic Kidney Disease who Are on Dialysis
4. Epoetin alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
5. Treatment of Anemic Patients with Cancer who are not Receiving Chemotherapy or Radiotherapy
Related Studies:
Other Anemia Clinical Trials
Other Illinois Clinical Trials
Other Chicago Clinical Trials
Exercise Plus Epoetin Alfa in Treating Cancer Patients Who Have Anemia-Related Fatigue
|
|
|
|
|
|
|
|
